新闻BenzingaReported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW Benzinga 2026.10.19 07:01 (GMT+0) 在Benzinga上打开 其他新闻 摩根士丹利维持对 Sportradar Gr 的“与大盘持平”评级，将目标价下调至 13.5 美元 摩根士丹利维持对 Simmons First Ntl 的减持评级，将目标价上调至 27 美元 富国银行维持对 EPR Properties 的“等权重”评级，将目标价下调至 56 美元 分析师看到了沃尔玛下一个重大广告机会中的数十亿美元潜力 摩根士丹利维持对 Red Rock Resorts 的“与大盘持平”评级，将目标价下调至 59 美元 EyePoint裁员并暂停临床试验，转而调整战略重点
